| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Aridis Pharmaceuticals Inc. | Aerucin (AR-105) | Pseudomonas aeruginosa | Phase 2 | Intravenous | Antibiotic | |
| Aridis Pharmaceuticals Inc. | AR-301 (tosatoxumab) | Ventilator associated pneumonia (VAP) / Staphylococcus aureus | Phase 3 | Looking for Funding | Intravenous | Antibiotic |
| Aridis Pharmaceuticals Inc. | AR-501 | Cystic Fibrosis | Phase 2a | Data Released | Inhalation | Respiratory |
| Aridis Pharmaceuticals Inc. | AR-501 | Cystic Fibrosis | Phase 2a | Data Released | Inhalation | Respiratory |
| Aridis Pharmaceuticals Inc. | Suvratoxumab (AR-320) - (SAATELLITE-2) | Staphylococcus aureus (S. aureus) | Phase 3 | Clinical Pause | Intravenous | Antibiotic |
| Aridis Pharmaceuticals Inc. | Suvratoxumab (AR-320) - (SAATELLITE-2) | Staphylococcus aureus (S. aureus) | Phase 3 | Clinical Pause | Intravenous | Antibiotic |
| Armata Pharmaceuticals Inc. | AP-PA02 - (Tailwind) | Non-cystic fibrosis bronchiectasis (NCFB) | Phase 2 | Data Released | Inhalation | Respiratory |
| ArriVent BioPharma Inc. | Firmonertinib - (ALPACCA) | First-line EGFR PACC mutant non-small cell lung (NSCLC) | Phase 3 | Enrollment Initiation | Oral | Oncology |